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Phenotypic spectrum and prevalence of INPP5E
mutations in Joubert Syndrome and related disorders
Lorena Travaglini1,2, Francesco Brancati1,3, Jennifer Silhavy4,5, Miriam Iannicelli1, Elizabeth Nickerson6,
Nadia Elkhartoufi7, Eric Scott4,5, Emily Spencer4,5, Stacey Gabriel6, Sophie Thomas7, Bruria Ben-Zeev8,
Enrico Bertini2, Eugen Boltshauser9, Malika Chaouch10, Maria Roberta Cilio11, Mirjam M de Jong12,
Hulya Kayserili13, Gonul Ogur14, Andrea Poretti9,15, Sabrina Signorini16, Graziella Uziel17, Maha S Zaki18,
the International JSRD Study Group, Colin Johnson19, Tania Attie´-Bitach7, Joseph G Gleeson4,5 and
Enza Maria Valente*,1,20
Joubert syndrome and related disorders (JSRD) are clinically and genetically heterogeneous ciliopathies sharing a peculiar
midbrain–hindbrain malformation known as the ‘molar tooth sign’. To date, 19 causative genes have been identified, all coding
for proteins of the primary cilium. There is clinical and genetic overlap with other ciliopathies, in particular with Meckel
syndrome (MKS), that is allelic to JSRD at nine distinct loci. We previously identified the INPP5E gene as causative of JSRD in
seven families linked to the JBTS1 locus, yet the phenotypic spectrum and prevalence of INPP5E mutations in JSRD and MKS
remain largely unknown. To address this issue, we performed INPP5E mutation analysis in 483 probands, including 408 JSRD
patients representative of all clinical subgroups and 75 MKS fetuses. We identified 12 different mutations in 17 probands
from 11 JSRD families, with an overall 2.7% mutation frequency among JSRD. The most common clinical presentation among
mutated families (7/11, 64%) was Joubert syndrome with ocular involvement (either progressive retinopathy and/or colobomas),
while the remaining cases had pure JS. Kidney, liver and skeletal involvement were not observed. None of the MKS fetuses
carried INPP5E mutations, indicating that the two ciliopathies are not allelic at this locus.
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INTRODUCTION
Joubert syndrome and related disorders (JSRD; MIM213300) are
clinically and genetically heterogeneous conditions characterized by
cerebellar vermis hypo-dysplasia and a peculiar midbrain–hindbrain
malformation, the ‘molar tooth sign’ (MTS). The typical neurological
features of hypotonia, ataxia, psychomotor delay, oculomotor apraxia
and neonatal breathing dysregulation are variably associated with a
broad spectrum of multiorgan abnormalities, mainly involving the
eyes, kidneys and liver.1 To date, up to 19 genes have been identified
with either autosomal recessive (INPP5E, TMEM216, AHI1, NPHP1,
CEP290, TMEM67, RPGRIP1L, ARL13B, CC2D2A, TTC21B, KIF7,
TCTN1, TCTN2, TMEM237, CEP41, TMEM138, C5orf42, TMEM231)
or X-linked inheritance (OFD1).2,3 Intriguingly, all JSRD genes code
for proteins of the primary cilium, making these disorders part of the
expanding group of ciliopathies.4 There is large clinical and genetic
overlap between JSRD and other ciliopathies such as Meckel
syndrome (MKS; MIM249000), isolated nephronophthisis (NPH;
MIM256100) and Senior-Loken syndrome (MIM266900). In
particular, JSRD and MKS are known to be allelic at nine loci,
suggesting that MKS represents the most severe end of the JSRD
clinical spectrum.2 It is estimated that known genes overall account
for about half of cases, suggesting further genetic heterogeneity;
moreover, genotype–phenotype correlates have been clearly estab-
lished only for few JSRD-causative genes.5–9
In 2009, Jacoby et al10 identified INPP5E mutations in a family
with MORM syndrome, a rare autosomal recessive condition related
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to Bardet–Biedl syndrome. In the same year, we identified homo-
zygous INPP5E mutations in seven consanguineous families geneti-
cally linked to the first JSRD locus (JBTS1) on 9q34.11 To better
define the phenotypic spectrum associated with INPP5E mutations
and to evaluate their potential contribution to MKS, here we
performed a comprehensive molecular screening of this gene in
nearly 500 probands diagnosed with either JSRD or MKS.
PATIENTS AND METHODS
Patients
Mutation analysis was performed in a total of 483 probands from two cohorts.
The first cohort consisted of 408 probands representative of the whole JSRD
clinical spectrum, selected from databases located at the IRCCS CSS-Mendel
Institute (Rome, Italy), the University of California San Diego (CA, USA) and
the Necker Hospital (Paris, France). All patients had neuroradiologically
proven MTS. For each patient, a detailed clinical questionnaire filled by the
referring clinician allowed to obtain information on the extent of multiorgan
involvement. In particular, nearly all patients underwent measurement of
renal and hepatic function, abdominal ultrasound, assessment of visual ability
and fundoscopy.
The second cohort included 75 fetuses diagnosed with MKS according on
established criteria,12 selected from databases located at the Necker Hospital
and the St James’s University Hospital (Leeds, UK). Most patients included in
this study had undergone mutation analysis of some JSRD/MKS genes as part
of published screenings or in subsequent research studies; probands known to
carry mutations in other genes were excluded from the screening. In proband
COR28, harboring only a single heterozygous INPP5E variant, mutations in,
the TMEM216, AHI1, NPHP1, CEP290, TMEM67, RPGRIP1L and TMEM138
genes have been previously excluded. Written informed consent was obtained
from all families, and the study was approved by the local ethics committees.
Molecular analysis
Genomic DNA was extracted from peripheral blood lymphocytes or frozen
tissue, following standard methods. The whole INPP5E (GenBank
NM_019892) coding region and splice sites were searched for mutations
adopting two distinct strategies. In 308 JSRD probands and in the 75 MKS
fetuses, bidirectional sequencing was performed using the BigDye terminator
chemistry and an ABI PRISM 3130Xl automated sequencer (Life Technolo-
gies, Carlsbad, CA, USA). One-hundred JSRD probands underwent whole-
exome sequencing (WES) using an Illumina HiSeq 2000 platform (Illumina,
San Diego, CA, USA) and the Agilent SureSelect Human All Exome 50 Mb kit
(Agilent, Santa Clara, CA, USA). In patient COR28, in whom only a single
heterozygous mutation could be detected, genomic quantitative real-time
PCR (qPCR) of all exons was performed to search for deletions or
duplications, as described.13 Primers and PCR conditions are available upon
request.
Bioinformatic analysis
For WES, the GATK software was used for variant identification.14 Thirteen
mutation description was checked using the Mutalyzer software (http://
www.humgen.nl/mutalyzer/1.0.1); for missense mutations, prediction of
pathogenicity was assessed using the PolyPhen-2 software (http://genetics.
bwh.harvard.edu/pph2/). Multiple sequence alignments of the human INPP5E
protein and its orthologues were generated using ClustalW (http://
www.ebi.ac.uk/clustalw/). Public databases were accessed using the following
links: dbSNP Build 132 (http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000
Genomes Project (http://www.1000genomes.org/), and Exome Sequencing
Project’s Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/).
RESULTS
The INPP5E mutational spectrum
Among JSRD, we identified 12 different INPP5E mutations in
17 patients from 11 families, with an overall prevalence of 2.7%
(11/408) (Table 1). This figure is likely to be slightly overestimated, as Ta
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we excluded from the screening a subset of about 50 probands known
to carry pathogenic mutations in other genes.
Ten mutations were novel, whereas two (p.R435Q, pR563H) had
been previously reported.11 Mutations were homozygous in eight
families and compound heterozygous in two. In COR28, only a single
mutated allele was found, and genomic qPCR failed to identify
deletions or duplications of INPP5E exons. Only one mutation was
nonsense (p.Y543X), while the remaining 11 were missense. Nearly all
changes were predicted as probably or possibly damaging by
Polyphen-2, clustered within the enzymatically active phosphatase
domain of the protein and affected residues that were highly
conserved among different species (Figure 1). None of the newly
identified mutations were encountered among 200 control chromo-
somes, nor have been previously reported as polymorphisms or rare
variants in public databases such as dbSNP, 1000 Genomes, and EVS.
All mutations segregated with the disease within families, insofar
parents were always heterozygous for one INPP5E mutation while all
affected members carried two mutations (with the exception of
COR28). In the cohort of 75 MKS fetuses, no pathogenic mutations
were found.
Phenotypes associated with INPP5E mutations
Detailed clinical features of patients bearing INPP5E mutations are
described in Table 1. Seven out of eleven families (64%) presented a
phenotype of JS with ocular involvement, consisting of either
progressive retinopathy, chorio-retinal colobomas, or both, while
the other four families had pure Joubert syndrome, only characterized
by neurological signs.
V
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Figure 1 Mutations identified in INPP5E. (a) Axial magnetic resonance imaging from six probands with mutations in INPP5E, showing the MTS.
(b) Schematic representation of the INPP5E protein consisting of four domains, including a proline rich domain, two small SH3 domains, a large conserved
300-amino-acid catalytic domain and a CAAX domain at C-terminus of the protein. Mutations identified in this article are reported above the panel, while
previously described mutations are shown below (the only MORM-associated mutation in shown in italic). Recurrent mutations are shown in bold.
(c) Conservation across species (shaded in yellow) of residues affected by the nine novel missense variants.
INPP5E mutations in Joubert syndrome
L Travaglini et al
1076
European Journal of Human Genetics
Interestingly, intra-familial variability was observed in some
families with multiple affected siblings. For instance, the affected sibs
in families COR199 and MTI-1521 were discordant for the presence
of either chorio-retinal coloboma or retinopathy. Similarly, the
severity of psychomotor delay varied widely in families COR64 and
MTI-1521, in which one affected sib presented mild or even absent
intellectual deficiency, while the other sibling(s) had a full blown
neurological phenotype.
DISCUSSION
Here, we present the first large-scale molecular screening of the
INPP5E gene in nearly 500 patients with diagnosis of JSRD or MKS,
two ciliopathies allelic at nine loci. Among JSRD, we identified 12
INPP5E mutations of which 10 novel, raising to 16 the number of
distinct pathogenic changes so far reported.10–11 We describe for the
first time a homozygous nonsense mutation (p.Y543X), resulting in
the production of a truncated protein lacking the final part of the
catalytic domain and the C-terminus transmembrane domain. All the
remaining mutations are missense changes affecting evolutionarily
conserved amino-acid residues clustered within or flanking the
enzymatically active phosphatase domain (Figure 1). INPP5E is a
member of the 5-ptase family, a class of enzymes that degrade
5-position phosphates from Phosphoinositides (PtdIns), thus regulat-
ing diverse cellular processes such as synaptic vesicle recycling, insulin
signaling, and embryonic development.15 In particular, INPP5E has
been shown to promote ciliary stabilization, and some mutations have
been previously shown to alter the INPP5E enzymatic activity and
promote premature cilia destabilization in response to specific
stimuli.10–11
Our data indicate a mutation prevalence of about 2.7% among
JSRD, while no pathogenic changes were detected in 75 MKS fetuses,
suggesting that INPP5E is not causative of the MKS phenotype. Lack
of allelism between these two conditions has been already described
for other ciliary genes such as ARL13B and CEP41, that are mutated
only in JSRD.16,17 It can be postulated that, at least during embryonic
development, the functioning of some ciliary proteins could be less
crucial than others or compensated by other proteins acting in the
same pathway, insofar even their complete loss of function would not
result in a lethal phenotype such as MKS. In fact, the only patient
harboring an INPP5E homozygous truncating mutation presented a
relatively mild phenotype of JS plus retinopathy and colobomas,
arguing against a specific correlation between the protein residual
function and phenotypic severity.
Including the present study, a total of 33 INPP5E-mutated patients
from 18 JSRD families have been described. Overall, the most
common presentation appears to be JS plus ocular involvement,
characterized by progressive retinopathy and/or chorio-retinal colo-
bomas (10/18, 56%). Interestingly, in these patients retinal disease was
never severe; in fact, none of them presented with Leber congenital
amaurosis, that is the typical retinopathy found in patients mutated in
CEP290.5 Pure JS is also a frequent presentation, occurring in five
families (28%), while other phenotypes such as JS with liver disease
(COACH syndrome) and JS with renal disease are extremely rare,
being reported only in two and one families, respectively. However, it
must be noted that age of examination of some patients was too
young to safely exclude the development of a progressive renal disease
such as NPH. The INPP5E phenotypic spectrum appears to largely
overlap with that related to AHI1 mutations;18 conversely, none of the
INPP5E-mutated patients presented polydactyly or encephalocele, two
features that are often associated with mutations in genes also
causative of MKS, such as TMEM216, CEP290, TMEM67 or
RPGRIP1L.5,19–21
In one patient with pure JS (COR28), only a single heterozygous
INPP5E mutation could be detected, despite complete sequencing
of the coding regions and canonical splice sites, and search for
genomic rearrangements. Although we cannot exclude the possibility
that a second pathogenic mutation resides within intronic or
regulatory regions of the gene, it is also plausible that the identified
change could act as a genetic modifier of the clinical phenotype in an
oligogenic context, and that digenic mutations may reside in another
gene. This intriguing mechanism has been already postulated for
several ciliopathies including Bardet–Biedl syndrome, NPH and even
JSRD,22–25 and could also help explain the intra-familial variability
observed in some INPP5E-mutated families. To this end, the
systematic genetic screening of multiple ciliopathy genes based
on innovative technologies such as next-generation-sequencing is
expected to give a main contribution to clarify the molecular basis
underlying the clinical complexity of JSRD and other ciliopathies.
NOTE ADDED IN PROOF
While this paper was being reviewed, two novel genes causative
of JSRD have been reported. These are TCTN3 (Thomas et al27) and
ZNF423 (Chaki et al28).
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